ZBIO Stock — Zenas BioPharma, Inc.: Metrics

Market overview

2 metrics

Share price

$31.98

Market cap

$2.17B

Price action

19 metrics

Price change (1W)

-5.3%

Price change (30D)

+2.7%

Price change (3M)

+86.7%

Price change (6M)

+27.0%

Price change (YTD)

-11.9%

Price change (1Y)

+99.9%

Trailing year

Price change (5Y)

—

52-week high

$43.17

52-week low

$15.20

Change from 52-week high

-25.9%

Change from 52-week low

+110.4%

Annualized volatility

109.7%

Beta

0.9

RSI (14D)

53.4

Price vs SMA 50

+6.8%

Price vs SMA 200

+22.9%

Avg volume (3M)

839,043

Relative volume

0.5

Average dollar volume

$23.09M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

65.18M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

2,058.3×

reciprocal yield 0.0%

P / book

8.3

reciprocal yield 12.0%

FCF yield

-11.0%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-23.5%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-03-16

Profitability

9 metrics

Gross margin

—

Operating margin

-3,830.6%

Trailing 12 months

Net margin

-3,777.4%

Gross profit (TTM)

—

Operating profit (TTM)

−$475.57M

Net income (TTM)

−$484.38M

Trailing 12 months

Diluted EPS (TTM)

$-9.62

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-143.15

Growth

11 metrics

Revenue growth YoY

+100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$1.00M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+50.8%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-196.0%

Return on assets

-69.0%

Debt / equity

—

Current ratio

9.9

EBITDA (TTM)

—

Free cash flow (TTM)

−$225.97M

Quick ratio

9.9

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$196.58M

Total assets

$701.69M

Total debt

$78.64M

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$225.97M

Capital expenditures (TTM)

$2,000

R&D (TTM)

$213.47M

SG&A (TTM)

—

Stock compensation (TTM)

$32.73M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

147

13F filer change QoQ

+6

Institutional ownership

94.5%

Short interest

3 metrics

Short interest

17.9%

Latest settlement · 21.1 days to cover

Days to cover

21.1d

Short-squeeze score

81 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

ZBIO · Zenas BioPharma, Inc.

ZBIO metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search